[go: up one dir, main page]

GR3030651T3 - Tgf-beta to improve neural outcome. - Google Patents

Tgf-beta to improve neural outcome.

Info

Publication number
GR3030651T3
GR3030651T3 GR990401737T GR990401737T GR3030651T3 GR 3030651 T3 GR3030651 T3 GR 3030651T3 GR 990401737 T GR990401737 T GR 990401737T GR 990401737 T GR990401737 T GR 990401737T GR 3030651 T3 GR3030651 T3 GR 3030651T3
Authority
GR
Greece
Prior art keywords
tgf
beta
nervous system
central nervous
injury
Prior art date
Application number
GR990401737T
Other languages
English (en)
Inventor
Peter Gluckman
Karoly Nikolics
Christopher Williams
Original Assignee
Genentech Inc
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Auckland Uniservices Ltd filed Critical Genentech Inc
Publication of GR3030651T3 publication Critical patent/GR3030651T3/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1841Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GR990401737T 1991-11-22 1999-06-30 Tgf-beta to improve neural outcome. GR3030651T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ24069691 1991-11-22
PCT/US1992/009974 WO1993009802A2 (en) 1991-11-22 1992-11-20 Tgf-beta to improve neural outcome

Publications (1)

Publication Number Publication Date
GR3030651T3 true GR3030651T3 (en) 1999-10-29

Family

ID=19923808

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990401737T GR3030651T3 (en) 1991-11-22 1999-06-30 Tgf-beta to improve neural outcome.

Country Status (9)

Country Link
EP (1) EP0625050B1 (el)
JP (2) JP4101284B2 (el)
AT (1) ATE178801T1 (el)
CA (1) CA2122058C (el)
DE (1) DE69228949T2 (el)
DK (1) DK0625050T3 (el)
ES (1) ES2133333T3 (el)
GR (1) GR3030651T3 (el)
WO (1) WO1993009802A2 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US5851832A (en) * 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US7361505B1 (en) 1991-07-08 2008-04-22 Neurospheres Holdings Ltd. Multipotent neural stem cell compositions
US6071889A (en) * 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
US6294346B1 (en) 1991-07-08 2001-09-25 Neurospheres Holdings, Ltd. Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
US6399369B1 (en) 1991-07-08 2002-06-04 Neurospheres Holdings Ltd. Multipotent neural stem cell cDNA libraries
US7166277B1 (en) 1991-07-08 2007-01-23 Neurospheres Holdings Ltd. Remyelination of neurons using multipotent neural stem cell progeny
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5980885A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
DE69434651T2 (de) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
US5650396A (en) * 1994-03-15 1997-07-22 Celtrix Pharmaceuticals, Inc. Methods of modulating inflammatory cytokines in the CNS using TGF-β
EP0904093A4 (en) 1996-03-22 2004-11-17 Gen Hospital Corp THE ADMINISTRATION OF GROWTH FACTOR POLYPEPTIDES AFTER AN ISCHEMICAL OF THE CENTRAL NERVOUS SYSTEM OR A TRAUMA
US7544511B2 (en) 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
CA2296056A1 (en) * 1997-07-10 1999-01-21 Keith Baker Methods for universally distributing therapeutic agents to the brain
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
ATE271886T1 (de) 1999-10-15 2004-08-15 Inst Genetics Llc Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
CA2449008A1 (en) 2001-06-01 2002-12-12 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US8293488B2 (en) 2002-12-09 2012-10-23 Neuralstem, Inc. Method for screening neurogenic agents
AU2003293409A1 (en) 2002-12-09 2004-06-30 Karl K. Johe Method for discovering neurogenic agents
CA2569978C (en) 2004-06-09 2017-06-06 The University Court Of The University Of Edinburgh Neural stem cells
WO2006055685A2 (en) 2004-11-17 2006-05-26 Neuralstem, Inc. Transplantation of human neural cells for treatment of neurodegenerative conditions
US20100158878A1 (en) 2008-12-23 2010-06-24 Alexandra Capela Target populations of oligodendrocyte precursor cells and methods of making and using same
MX341316B (es) 2010-07-28 2016-08-15 Neuralstem Inc * Poblacion de celulas madre neurales para tratar y/o revertir enfermedades y/o trastornos neurodegenerativos.
AU2015336194B2 (en) 2014-10-20 2019-01-03 Neuralstem, Inc. Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof

Also Published As

Publication number Publication date
EP0625050A1 (en) 1994-11-23
CA2122058A1 (en) 1993-05-27
JP4101284B2 (ja) 2008-06-18
DE69228949D1 (de) 1999-05-20
JPH07501080A (ja) 1995-02-02
CA2122058C (en) 2001-07-31
JP2004115532A (ja) 2004-04-15
DK0625050T3 (da) 1999-10-25
DE69228949T2 (de) 1999-09-16
ES2133333T3 (es) 1999-09-16
WO1993009802A2 (en) 1993-05-27
ATE178801T1 (de) 1999-04-15
EP0625050B1 (en) 1999-04-14

Similar Documents

Publication Publication Date Title
GR3030651T3 (en) Tgf-beta to improve neural outcome.
HU9402771D0 (en) Pharmaceutical compositions for wound healing and treatment of fibrotic disorders
PH31072A (en) Azaheterocyclylmethyl-chromans for treating anxiety.
EP1555025A3 (en) Use of dehydroepiandrosterone analogs for the treatment of asthma
PH24867A (en) A method of treating conditions associated with photodamaged skin by using pharmaceutical compositions containing p(22-(5,6,7,8 tetrahydro-5,5,8,8-tetramethyl-2-naphtyl)propenyl)phenylsulfone and derivatives thereof
AU6586896A (en) Fatty acid treatment
WO1995017154A3 (en) Use of thalidomide for treating neurocognitive disorders
ZA924953B (en) Method of treating ocular inflammation
CA2122340A1 (en) Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
MY106528A (en) Method of treating impotence.
AU8091787A (en) The use of paroxetine to treat pain
ATE102830T1 (de) Methode zur behandlung des interstitiellen blasenentzuendung.
BR9305909A (pt) Composto de 4-aminopiridina a ser usado no tratamento de uma condição que afeta o sistema nervoso e respectiva embalagem comercial
PT655243E (pt) Derivados da melatonina para utilizacao no tratamento de disturbios do sono
GB9500024D0 (en) Treatment of excessive cell proliferation disorders
NZ307601A (en) Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions
AU2060783A (en) Morphine-vitamin b12 analgesic treatment
EP0495998A4 (el)
OA09788A (en) "Pharmaceutical compositions for the treatment of B-cell malignancies".
RU93044256A (ru) Способ лечения саркоидоза
JPS5415356A (en) Coagulating and settling method
JPS56128722A (en) Removal of antiacetylcholinereceptor antibody and device therefor
GR3019327T3 (en) An imidazobenzodiazepin for treating sleep disorders
UA19610A (uk) Спосіб лікуваhhя опісторхозhої іhвазії
刘丽军 et al. ELECTROACUPUNCTURE TREATMENT OF 30 CASES OF HYPERPLASIA OF MAMMARY GLANDS